# US 2005/0232899 A1 · Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232899 A1
- Document ID: US20050232899A1
- Status: Published application
- Kind: A1
- Application number: 10/927,518
- Filed: 2004-08-25
- Published: 2005-10-20
- Earliest claimed: 2002-05-31
- Assignees: Aradigm Corporation
- Inventors: Gul Balwani; Brooks Boyd; John Whatley
- Web page: https://patentgrep.com/patent/US20050232899A1

## CPC

- A61K 38/212: {IFN-alpha}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 38/21: Interferons {[IFN]}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon, and proteins in general, for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.

## Claims

### Claim at position 1

1-78. (canceled)

### Claim 79

A stable, aqueous formulation of a biologically active human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising: about 0.5 to about 12.0 mg of biologically active human protein per mL of the formulation; about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation; about 0.45 to about 0.60 mg Na2HPO4.7H2O per mL of the formulation; at least about 0.5 mg Polysorbate 20 per mL of the formulation; and water for injection as the solvent; wherein the amounts of Na2HPO4.7H2O and Na2HPO4.7H2O are adjusted to bring the pH of the formulation to about 7.0 to 8.0.

### Claim 80 (depends on 79)

The formulation of claim 79, wherein said protein comprises alpha-2b interferon and wherein the concentration of protein is about 4.0 to 8.0 mg per mL of solution.

### Claim 81 (depends on 79)

The formulation of claim 79, wherein said protein consists of alpha-2b interferon and wherein the concentration of protein is about 5.0 to 6.0 mg per mL of solution.

### Claim 82 (depends on 81)

The formulation of claim 81, wherein the concentration of protein is about 5.56 mg per mL of solution and wherein the concentration of Polysorbate 20 is about 1.0 to about 2.0 mg/mL of the formulation.

### Claim 83 (depends on 79)

The formulation of claim 79, wherein the protein is alpha interferon and the concentration of alpha interferon is about 5.0 to about 6.0 mg per mL of the formulation, the concentration of Polysorbate 20 is about 1.00 to about 1.50 mg per mL of the formulation, and the amounts of Na2HPO4.7H2O and Na2HPO4.7H2O are adjusted to bring the pH of the formulation to about 7.4 to 7.6.

### Claim 84 (depends on 83)

The formulation of claim 83, wherein said alpha interferon comprises alpha-2b interferon.

### Claim 85

A stable, aqueous formulation of alpha interferon for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising: about 0.5 to about 12.0 mg alpha interferon per mL of the formulation; a buffer system capable of maintaining the pH of the formulation within the range of about 7.0 to 8.0; a poly(oxy-1,2-ethanediyl) derivative; and water.

### Claim 86 (depends on 85)

The formulation of claim 85, wherein said buffer system comprises about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation and about 0.45 to about 0.60 mg Na2HPO4.7H2O per mL of the formulation;
wherein said poly(oxy-1,2-ethanediyl) derivative comprises Polysorbate 20; and
wherein said Polysorbate 20 is added at a concentration of at least about 0.5 mg per mL of the formulation.

### Claim 87 (depends on 85)

The formulation of claim 85, wherein said poly(oxy-1,2, ethanediyl) derivative is added at a concentration of about 1.0 to about 2.0 mg per mL of the formulation.

### Claim 88

A stable, aqueous formulation of alpha interferon for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising: about 5.5 to about 5.6 mg alpha-2b interferon per mL of the formulation; about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation; about 0.45 to about 0.60 mg Na2HPO4.7H2O per mL of the formulation; at least about 0.5 mg Polysorbate 20 per mL of the formulation; and water for injection as the solvent; wherein the amounts of Na2HPO4.7H2O and Na2HPO4.7H2O are adjusted to bring the pH of the formulation to about 7.4 to 7.6.

### Claim 89 (depends on 88)

The formulation of claim 88, comprising about 1.0 to about 2.0 mg of said Polysorbate 20 per mL of the formulation.

### Claim 90

An article of manufacture comprising:
a sterilized filling vessel; and
a stable, aqueous formulation of biologically active human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising about 0.5 to about 12.0 mg of biologically active human protein per mL of the formulation; a buffer system capable of maintaining the pH of the formulation within the range of about 7.0 to 8.0; a sorbitan, monododecanoate; and water;
wherein said protein is alpha-2b interferon;
wherein said sterilized filling vessel comprises a single dose container which is adapted to be sealed after receiving said formulation, wherein said single dose container is a blister pack and wherein about 45 microliters to about 2.5 microliters of said formulation are contained by said blister pack.

### Claim 91

An article of manufacture comprising:
a sealed, sterile blister pack containing a stable, aqueous formulation of biologically active human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising about 0.5 to about 12.0 mg biologically active human protein per mL of the formulation; a buffer system capable of maintaining the pH of the formulation within the range of about 7.0 to 8.0; a poly(oxy-1,2-ethanediyl) derivative; and water.

### Claim 92 (depends on 91)

The article of manufacture of claim 91, wherein said buffer system comprises about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation and about 0.45 to about 0.60 mg NaH2PO4.2H2O per mL of the formulation; and
wherein said poly(oxy-1,2-ethanediyl) derivative comprises high purity Polysorbate 20 added at a concentration of about 1.00 to about 2.00 mg per mL of the formulation.

### Claim 93 (depends on 92)

The article of manufacture of claim 92, wherein amounts of said Na2HPO4.7H2O and NaH2PO4.2H2O are adjusted to make the pH of the formulation about 7.4 to about 7.6, and wherein said protein is alpha interferon and said alpha interferon has a concentration of about 4.0 to about 8.0 mg per mL of the formulation.

### Claim 94

A method of providing a biologically active human protein in a form and concentration able to be systemically delivered to a patient via the lungs, said method comprising the steps of: providing a biologically active human protein solution having a known, selected biological activity, and containing a buffering system and a stabilizing agent; and aerosolizing the solution to form an aerosol of aqueous droplets, wherein the aerosol has a fine particle fraction of at least about 50 percent.

### Claim 95 (depends on 94)

The method of claim 94, wherein the aerosol has a fine particle fraction of about 90 to 100 percent and wherein said fine particle fraction comprises particles having a mass median aerodynamic diameter chosen less than about 6.5 microns, less than about 5 microns and less than about 3.5 microns.

### Claim 96

An aerosolized stable, aqueous formulation of a recombinantly produced, biologically active, human protein for aerosol delivery, said formulation being free of human blood-derived products and animal blood-derived products, said formulation comprising:
about 4.0 to about 12.0 mg recombinantly produced, biologically active, human protein per mL of the formulation;
about 5.5 to about 6.0 mg Na2HPO4.7H2O per mL of the formulation;
about 0.45 to about 0.60 mg NaH2PO4.2H2O per mL of the formulation;
at least about 0.5 mg Polysorbate 20 per mL of the formulation; and
water for injection as the solvent; wherein the amounts of Na2HPO4.7H2O and NaH2PO4.2H2O are adjusted to bring the pH of the formulation to about 7.0 to 8.0 and the aerosol is comprised of particles have an aerodynamic diameter in a range of from about 1 micron to about 12 microns.

### Claim 97 (depends on 96)

The formulation of claim 96, wherein the formulation has a pH in a range from about 7.2 to about 7.6 and the particles have an aerodynamic diameter in a range of from about 2 microns to about 6 microns and wherein the concentration of protein is about 4.0 to 8.0 mg per mL of solution.

### Claim 98 (depends on 96)

The formulation of claim 96, wherein the protein is chosen from interferons, including alpha type, beta type and gamma type; growth hormone; G-CSF; GM-CSF; M-CSF; melanocyte stimulating hormone; antibodies, including monoclonal antibodies, and Fab fragments thereof; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha.-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or tissue-type plasminogen activator (t-PA); bombazine; thrombin; tumor necrosis factor-.alpha. and -.beta.; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-.alpha.); mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; DNase; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; an integrin; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF-.beta.; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-.alpha. and TGF-.beta., including TGF-.beta. 1, TGF-.beta.2, TGF-.beta.3, TGF-.beta.4, or TGF-.beta.5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I); insulin-like growth factor binding proteins; CD proteins such as CD3, CD4, CD8, CD19 and CD20; erythropoietin (EPO); thrombopoietin (TPO); osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as interferon-.alpha., -.beta., and -.gamma.; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxide dismutase; T-ell receptors; surface membrane proteins; decay accelerating factor (DAF); a viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; immunoadhesins; synthetic peptides; and biologically active fragments or variants of any of the above-listed polypeptides.
